Literature DB >> 9336132

Predicting radiation response.

M V Graham.   

Abstract

Mesh:

Year:  1997        PMID: 9336132     DOI: 10.1016/s0360-3016(97)00353-2

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


× No keyword cloud information.
  5 in total

1.  Analysis of dose-volume parameters predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-conformal radiation therapy or IMRT.

Authors:  Gaurav Kumar; Sheh Rawat; Abhishek Puri; Manoj Kumar Sharma; Pranav Chadha; Anand Giri Babu; Girigesh Yadav
Journal:  Jpn J Radiol       Date:  2011-12-14       Impact factor: 2.374

2.  Analysis of related factors associated with radiation pneumonitis in patients with locally advanced non-small-cell lung cancer treated with three-dimensional conformal radiotherapy.

Authors:  Jun Dang; Guang Li; Xiaobe Lu; Lei Yao; Shuo Zhang; Zhan Yu
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-04       Impact factor: 4.553

3.  Analysis of clinical and dosimetric factors associated with severe acute radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemotherapy and intensity-modulated radiotherapy.

Authors:  Anhui Shi; Guangying Zhu; Hao Wu; Rong Yu; Fuhai Li; Bo Xu
Journal:  Radiat Oncol       Date:  2010-05-12       Impact factor: 3.481

Review 4.  Radiation Oncology: Future Vision for Quality Assurance and Data Management in Clinical Trials and Translational Science.

Authors:  Linda Ding; Carla Bradford; I-Lin Kuo; Yankhua Fan; Kenneth Ulin; Abdulnasser Khalifeh; Suhong Yu; Fenghong Liu; Jonathan Saleeby; Harry Bushe; Koren Smith; Camelia Bianciu; Salvatore LaRosa; Fred Prior; Joel Saltz; Ashish Sharma; Mark Smyczynski; Maryann Bishop-Jodoin; Fran Laurie; Matthew Iandoli; Janaki Moni; M Giulia Cicchetti; Thomas J FitzGerald
Journal:  Front Oncol       Date:  2022-08-10       Impact factor: 5.738

5.  Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.

Authors:  M Yamada; S Kudoh; H Fukuda; K Nakagawa; N Yamamoto; Y Nishimura; S Negoro; K Takeda; M Tanaka; M Fukuoka
Journal:  Br J Cancer       Date:  2002-07-29       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.